SOLSTICE: Combination Therapy for the Treatment of Chronic Hepatitis D Infection
Status:
Not yet recruiting
Trial end date:
2026-12-01
Target enrollment:
Participant gender:
Summary
This is a phase 2 trial in which participants with chronic hepatitis D virus (HDV) infection
will receive VIR-2218 and/or VIR-3434 and be assessed for safety, tolerability, and efficacy